ArticleBlood2011
High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 60 citations in OpenAlex.
- Targeting CD47 in Sézary syndrome with SIRPαFc.Blood advances · 2019Trial
- Review
- Mycosis Fungoides, Sézary Syndrome, and Cutaneous B-Cell Lymphomas: 2025 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2025Review
- The overlap of skin and blood T-cell clones in early-stage mycosis fungoides.Blood advances · 2023Article
- Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatment.Blood advances · 2023Article
- Molecular treatment trajectories within psoriatic T lymphocytes: a mini review.Frontiers in immunology · 2023Review
- Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.American journal of hematology · 2023Article
- TOX Outperforms FOXP3, CD4 and GATA3 in Histopathological Diagnosis of Early Mycosis Fungoides.Turk patoloji dergisi · 2023Article
- Large-cell transformation is an independent poor prognostic factor in Sézary syndrome: analysis of 117 cases.The British journal of dermatology · 2022Article
- [New insights into the pathogenesis and molecular understanding of cutaneous T-cell lymphomas].Dermatologie (Heidelberg, Germany) · 2022Review
- Malignant and Benign T Cells Constituting Cutaneous T-Cell Lymphoma.International journal of molecular sciences · 2021Review
- Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.American journal of hematology · 2021Article
- Necrotizing lymphadenitis : A case report and literature review.Zeitschrift fur Rheumatologie · 2021Review
- Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification.Cytometry. Part B, Clinical cytometry · 2019Article
- Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR.Blood advances · 2019Article
- Single-cell heterogeneity in Sézary syndrome.Blood advances · 2018Article
- Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.Molecular cancer therapeutics · 2017Article
- Cutaneous T-cell Lymphoma.Clinics in laboratory medicine · 2017Review
- The biomarker landscape in mycosis fungoides and Sézary syndrome.Experimental dermatology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
In early-stage cutaneous T-cell lymphoma (CTCL), malignant T cells are confined to skin and are difficult to isolate and discriminate from benign reactive cells. We found that T cells from CTCL skin lesions contained a population of large, high-scatter, activated skin homing T cells not observed in other inflammatory skin diseases. High-scatter T (T(HS)) cells were CD4(+) in CD4(+) mycosis fungoides (MF), CD8(+) in CD8(+) MF, and contained only clonal T cells in patients with identifiable malignant Vβ clones. T(HS) cells were present in the blood of patients with leukemic CTCL, absent in patients without blood involvement, and contained only clonal malignant T cells. The presence of clonal T(HS) cells correlated with skin disease in patients followed longitudinally. Clonal T(HS) cells underwent apoptosis in patients clearing on extracorporeal photopheresis but persisted in nonresponsive patients. Benign clonal T-cell proliferations mapped to the normal low-scatter T-cell population. Thus, the malignant T cells in both MF and leukemic CTCL can be conclusively identified by a unique scatter profile. This observation will allow selective study of malignant T cells, can be used to discriminate patients with MF from patients with other inflammatory skin diseases, to detect peripheral blood involvement, and to monitor responses to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.